STOCK TITAN

Hims & Hers (HIMS) insider plans $770K share sale under Rule 144

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Hims & Hers Health, Inc. (HIMS) filed a Form 144 reporting that insider Michael Y. Chi plans to sell up to 13,750 Class A shares through Fidelity Brokerage on or after 07/23/2025. At the stated aggregate market value of $770,000, the sale equals roughly 0.006 % of the company’s 215,453,899 shares outstanding, implying minimal dilution or governance impact.

The shares stem from option exercises dated 02/24/2022, 08/10/2022 and 03/01/2023, all paid in cash on 07/23/2025. Chi has already sold 27,602 shares in the prior three months, generating $1.62 million in gross proceeds at prices recorded on 06/06, 06/10 and 06/17 2025.

Although the volume is modest versus float, continued dispositions may be interpreted by some investors as an insider sentiment signal. No new operational or financial metrics are included in the filing.

Positive

  • Sale volume is only 0.006 % of shares outstanding, implying negligible dilution or control impact.
  • Transparent Rule 144 disclosure allows investors to monitor insider activity in real time.

Negative

  • Continued insider selling (41,352 shares including planned sale) within four months can be perceived as a bearish sentiment signal.
  • No accompanying business updates to offset potential negative perception of insider dispositions.

Insights

TL;DR – Small, routine insider sale; negligible balance-sheet impact, watch sentiment.

The proposed sale of 13,750 shares (~$0.77 M) is immaterial to HIMS’s 215 M share base. Coupled with 27.6 k shares sold since June, the pattern looks like ongoing liquidity from option exercises rather than strategic divestment. No fundamentals change; therefore, the filing is neutral in valuation terms, but repeated selling could weigh on short-term sentiment for momentum traders.

TL;DR – Governance neutral; disclosure complies, but insider selling trend bears monitoring.

Chi’s sale is properly disclosed under Rule 144 and represents <0.01 % of shares, posing no control risk. However, incremental insider dispositions—three in the last quarter plus this notice—may attract scrutiny from investors tracking insider confidence metrics. Absent larger aggregated sales or undisclosed adverse information (affirmatively denied in the form), governance concern is low.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many HIMS shares does Michael Y. Chi plan to sell under this Form 144?

Chi intends to sell 13,750 Class A shares with an estimated value of $770,000.

What percentage of Hims & Hers Health’s outstanding shares does the proposed sale represent?

Roughly 0.006 % of the 215,453,899 shares outstanding.

Have there been recent insider sales by the same individual?

Yes. Chi sold 27,602 shares between 06/06/2025 and 06/17/2025 for $1.62 million in gross proceeds.

When is the earliest date the shares may be sold?

The approximate sale date disclosed is 07/23/2025 via the NYSE.

Are these shares newly issued or option-exercised?

They arise from option exercises granted in 2022 and 2023, paid for in cash on 07/23/2025.

Does the filing include any financial performance data for HIMS?

No. Form 144 only addresses proposed insider share sales and contains no operational or earnings metrics.
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

HIMS Latest News

HIMS Latest SEC Filings

HIMS Stock Data

7.52B
204.78M
10.63%
88.99%
33.02%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO